These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31628201)

  • 1. Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis.
    Chiba A; Bawaneh A; Velazquez C; Clear KYJ; Wilson AS; Howard-McNatt M; Levine EA; Levi-Polyachenko N; Yates-Alston SA; Diggle SP; Soto-Pantoja DR; Cook KL
    Mol Cancer Res; 2020 Jan; 18(1):130-139. PubMed ID: 31628201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Herrada J; Iyer RB; Atkinson EN; Sneige N; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 1997 Sep; 3(9):1565-9. PubMed ID: 9815844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
    Cohen LF; Breslin TM; Kuerer HM; Ross MI; Hunt KK; Sahin AA
    Am J Surg Pathol; 2000 Sep; 24(9):1266-72. PubMed ID: 10976701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
    Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
    J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
    Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
    Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.
    Brady EW
    Breast J; 2002; 8(2):97-100. PubMed ID: 11896755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2019 May; 20(5):1511-1518. PubMed ID: 31128056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection.
    van Rijk MC; Nieweg OE; Rutgers EJ; Oldenburg HS; Olmos RV; Hoefnagel CA; Kroon BB
    Ann Surg Oncol; 2006 Apr; 13(4):475-9. PubMed ID: 16485148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
    Dominici LS; Negron Gonzalez VM; Buzdar AU; Lucci A; Mittendorf EA; Le-Petross HT; Babiera GV; Meric-Bernstam F; Hunt KK; Kuerer HM
    Cancer; 2010 Jun; 116(12):2884-9. PubMed ID: 20564395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.